IQVIA (IQV) to Release Quarterly Earnings on Tuesday

IQVIA (NYSE:IQV) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of $3.02 per share and revenue of $4.3020 billion for the quarter. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 9:00 AM ET.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the previous year, the company posted $2.70 EPS. IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. On average, analysts expect IQVIA to post $12 EPS for the current fiscal year and $13 EPS for the next fiscal year.

IQVIA Trading Up 0.4%

Shares of NYSE IQV opened at $208.22 on Friday. The firm has a 50 day moving average price of $188.23 and a two-hundred day moving average price of $187.38. The stock has a market cap of $34.75 billion, a P/E ratio of 25.80, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20. IQVIA has a 52-week low of $154.50 and a 52-week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently modified their holdings of the business. Boston Partners acquired a new stake in IQVIA in the 3rd quarter valued at $676,698,000. Orbis Allan Gray Ltd raised its holdings in IQVIA by 96.5% during the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after buying an additional 933,554 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after buying an additional 879,701 shares in the last quarter. Viking Global Investors LP bought a new position in shares of IQVIA in the fourth quarter valued at $139,582,000. Finally, FIL Ltd grew its holdings in shares of IQVIA by 76.7% during the fourth quarter. FIL Ltd now owns 1,063,236 shares of the medical research company’s stock valued at $239,664,000 after buying an additional 461,614 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a report on Thursday, July 9th. Mizuho raised their price target on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Finally, Robert W. Baird lifted their target price on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $225.71.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.